ACADIA Pharmaceuticals Inc Earnings

The next earnings date for ACADIA Pharmaceuticals Inc is November 11, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of ACADIA Pharmaceuticals Inc Earnings

Report DateEstimated Earnings Per Share
11/11/2025$0.14

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

ACADIA Pharmaceuticals Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
07/30/2025---$0-100.00%
05/06/2025Before Market$0.11120.00%
02/25/2025Before Market$0.86292.69%
11/06/2024After Market$0.2042.86%
08/06/2024After Market$0.2011.11%
05/08/2024After Market$0.10100.00%
02/27/2024After Market$0.28-6.67%
11/02/2023After Market$-0.406.98%
08/02/2023After Market$0.01112.50%
05/08/2023After Market$-0.27-28.57%
02/27/2023After Market$-0.26-8.33%
11/02/2022After Market$-0.1710.53%
08/08/2022After Market$-0.2116.00%
05/04/2022After Market$-0.3345.00%
02/28/2022After Market$-0.27-12.50%
11/08/2021After Market$-0.0965.38%
08/04/2021After Market$-0.2710.00%
05/05/2021After Market$-0.4220.75%
02/24/2021After Market$-0.4210.64%
11/04/2020After Market$-0.54-42.11%
08/05/2020After Market$-0.2738.64%
05/07/2020After Market$-0.57-18.75%
02/26/2020After Market$-0.345.56%
10/30/2019After Market$-0.2927.50%
07/31/2019After Market$-0.3815.56%
05/01/2019After Market$-0.59-13.46%
02/26/2019After Market$-0.509.09%
11/06/2018After Market$-0.5013.79%
08/08/2018After Market$-0.51-13.33%
05/04/2018Before Market$-0.4420.00%
02/27/2018After Market$-0.555.17%
11/07/2017After Market$-0.5314.52%
08/08/2017After Market$-0.5523.61%
05/09/2017After Market$-0.721.37%
02/28/2017After Market$-0.650.00%
11/07/2016After Market$-0.61-8.93%
08/04/2016After Market$-0.63-28.57%
05/05/2016After Market$-0.45-7.14%
02/29/2016Before Market$-0.45-18.42%
11/05/2015After Market$-0.392.50%
08/06/2015After Market$-0.39-18.18%
05/07/2015After Market$-0.40-48.15%
02/26/2015After Market$-0.28-7.69%
11/10/2014After Market$-0.25-13.64%
08/05/2014---$-0.22-15.79%
05/06/2014---$-0.19-46.15%
02/27/2014---$-0.130.00%
11/06/2013---$-0.120.00%
08/06/2013---$-0.11-22.22%
05/07/2013---$-0.080.00%
03/12/2013---$-0.11-22.22%
11/05/2012---$-0.0455.56%
08/08/2012---$-0.1016.67%
05/08/2012---$-0.12-9.09%
03/06/2012---$-0.100.00%
11/09/2011---$-0.100.00%
08/10/2011---$-0.1214.29%
05/10/2011---$-0.12-9.09%
03/10/2011---$0.747.25%
11/09/2010---$-0.1135.29%
08/09/2010---$-0.1131.25%
05/10/2010---$-0.1417.65%
03/09/2010---$-0.20-5.26%
11/09/2009---$-0.234.17%
08/05/2009---$-0.340.00%
05/11/2009---$-0.40-11.11%
03/09/2009---$-0.38-2.70%
11/05/2008---$-0.426.67%
08/05/2008---$-0.49-6.52%
05/05/2008---$-0.444.35%
03/05/2008---$-0.460.00%
11/05/2007---$-0.43-13.16%
08/06/2007---$-0.2925.64%
05/08/2007---$-0.422.33%
03/06/2007---$-0.424.55%
11/06/2006---$-0.385.00%
08/08/2006---$-0.43-19.44%
05/10/2006---$-0.39-11.43%
03/01/2006---$-0.44-15.79%
11/10/2005---$-0.53-76.67%
08/10/2005---$-0.2610.34%
05/11/2005---$-0.3122.50%
03/03/2005---$-0.44-7.32%
11/10/2004---$-0.370.00%
08/11/2004---$-0.4236.36%

More About ACADIA Pharmaceuticals Inc

Website
https://www.acadia.com
Country
USA
Full Time Employees
653

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

“ACADIA Pharmaceuticals Inc Earnings” Can Refer to the ACADIA Pharmaceuticals Inc Earnings Date

Some people say “ACADIA Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my ACADIA Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning ACADIA Pharmaceuticals Inc Stock on the Earnings Date

If you own ACADIA Pharmaceuticals Inc stock (ACAD) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for ACADIA Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading ACADIA Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More ACADIA Pharmaceuticals Inc Earnings

You can contact us any time if you would like to ask questions about ACADIA Pharmaceuticals Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.